SEC Comment Letter for Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306) (TNXP) — Oct 25, 2019
Tonix Pharmaceuticals Holding Corp. (TNXP) (CIK 0001430306)
Date: Oct. 25, 2019 · CIK: 0001430306 · Accession: 0000000000-19-014868
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234263
Letter
October 25, 2019 Seth Lederman Chief Executive Officer Tonix Pharmaceuticals Holding Corp. 509 Madison Avenue, Suite 1608 New York, NY 10022 Re:Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-1 Filed October 18, 2019 File No. 333-234263 Dear Mr. Lederman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joseph McCann at (202) 551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
October 25, 2019
Seth Lederman
Chief Executive Officer
Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue, Suite 1608
New York, NY 10022
Re:Tonix Pharmaceuticals Holding Corp.
Registration Statement on Form S-1
Filed October 18, 2019
File No. 333-234263
Dear Mr. Lederman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joseph McCann at (202) 551-6262 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences